1.Department of Hepatopancreatobiliary
Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi
830011, China; 2.Department of Hepatobiliary
Surgery, The First Affiliated Hospital, Xinjiang Medical University,
Urumqi 830054, China; 3.Department of General
Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang
University, Hangzhou 310016, China;
Abstract：This study aimed to investigate the effect of adjuvant therapy on the treatment of stage II pancreatic carcinomas. The clinical data of 139 cases of stage II pancreatic carcinoma were analyzed retrospectively. The overall 1-, 3-, and 5-year cumulative survival rates of 139 patients were 40%, 6%, and 3%, respectively, and the median survival time (MST) was 279 days. The MST was 399 days for those with adjuvant therapy, 210 days for those without adjuvant therapy, 390 days for the radical resection group, 270 days for the bypass operation and laparotomy group, and 132 days for the nonsurgical group. The adjuvant therapy could not prolong the survival time and decrease the liver metastasis rate of the patients with stage II carcinoma significantly in radical resection group (P>0.05). In the bypass operation and laparotomy group and nonsurgical group, the adjuvant therapy could improve the survival of the patients significantly (P<0.05); however, the survival rate was not significantly different among systemic venous chemotherapy, radiation therapy, interventional therapy, and combination therapy (P>0.05); or between gemcitabine (GEM) regimen and 5-fluorouracil regimen (P>0.05); or between GEM monotherapy and GEM combined with platinum/capecitabine (P>0.05). The proper adjuvant therapy can be suggested according to the general condition of the patients after radical resection for stage II pancreatic carcinoma. Chemotherapy combined with radiation should be applied actively for the patients whose cancerous tissues were not radically resected. The clinical efficacy of GEM combined with platinum/capecitabine is relatively better than GEM.
. Influence of the adjuvant therapy on the survival
of patients with stage II pancreatic carcinoma[J]. Front. Med., 2010, 4(4): 430-435.
Xi-Yan WANG, Hai-Jun LI, Dong YAN, Hao WEN, Shu-Yong PENG, . Influence of the adjuvant therapy on the survival
of patients with stage II pancreatic carcinoma. Front. Med., 2010, 4(4): 430-435.
Kern S, Hruban R, Hollingsworth M A, Brand R, Adrian T E, Jaffee E, Tempero M A. A white paper: the product of a pancreas cancer thinktank. Cancer Res, 2001, 61(12): 4923–4932 PMID: 11406572
Au E. Clinical update of gemcitabine in pancreas cancer. Gan To Kagaku Ryoho, 2000, 27(Suppl 2): 469–473 PMID: 10895197
Wagner M, Redaelli C, Lietz M, Seiler C A, Friess H, Büchler M W. Curative resection is thesingle most important factor determining outcome in patients withpancreatic adenocarcinoma. Br J Surg, 2004, 91(5): 586–594 doi:10.1002/bjs.4484 PMID: doi: 10.1002/bjs.4484 15122610 doi: 10.1002/bjs.4484
Yekebas E F, Bogoevski D, Cataldegirmen G, Kunze C, Marx A, Vashist Y K, Schurr P G, Liebl L, Thieltges S, Gawad K A, Schneider C, Izbicki J R. En bloc vascular resection for locally advanced pancreatic malignanciesinfiltrating major blood vessels: perioperative outcome and long-termsurvival in 136 patients. Ann Surg, 2008, 247(2): 300–309 doi:10.1097/SLA.0b013e31815aab22 PMID: doi: 10.1097/SLA.0b013e31815aab22 18216537 doi: 10.1097/SLA.0b013e31815aab22
Sun C Y, Chen Z L. Attach Importance of Combined Modality Therapy for Pancreatic Carcinomas. Zhonghua Xiao Hua Wai Ke Za Zhi, 2009, 8(4): 244–246 (in chinese)
Cheng D H, Liu Y F. TNM staging of pancreatic carcinomas. Zhongguo Shi Yong Wai Ke Za Zhi, 2004, 24(5): 320 (in chinese)
Wu W D, Peng C H, Zhao D J, Zhou G W, Xiao W D, Li H W. The importance of superior mesenteric-portal vein resectionfor radical duodenopancreatectomy of pancreatic adenocarcinoma. Zhonghua Pu Tong Wai Ke Za Zhi, 2006, 21(9): 620–622 (in chinese)
Qin R Y, Zou S Q, Qiu F Z. The technique of radical pancreaticoduodenectomyfor malignant tumor in pancreatic head with pressed superior mesentericblood vessels or portal vein. Zhonghua Wai Ke Za Zhi, 2008, 46(5): 366–369 (in chinese) PMID: 18785534
Cress R D, Yin D, Clarke L, Bold R, Holly E A. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control, 2006, 17(4): 403–409 doi:10.1007/s10552-005-0539-4 PMID: doi: 10.1007/s10552-005-0539-4 16596292 doi: 10.1007/s10552-005-0539-4
Saif M W. Is there a standard of care for the management of advancedpancreatic cancer? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25―27, 2008. JOP, 2008, 9(2): 91–98 PMID: 18326919
Wray C J, Ahmad S A, Matthews J B, Lowy A M. Surgery for pancreatic cancer: recent controversies andcurrent practice. Gastroenterology, 2005, 128(6): 1626–1641 doi:10.1053/j.gastro.2005.03.035 PMID: doi: 10.1053/j.gastro.2005.03.035 15887155 doi: 10.1053/j.gastro.2005.03.035
Saif M W. Pancreatic cancer: highlights from the 42nd annual meetingof the American Society of Clinical Oncology, 2006. JOP, 2006, 7(4): 337–348 PMID: 16832131
Neoptolemos J P, Stocken D D, Friess H, Bassi C, Dunn J A, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr D J, Büchler M W. A randomized trial of chemoradiotherapyand chemotherapy after resection of pancreatic cancer. N Engl J Med, 2004, 350(12): 1200–1210 doi:10.1056/NEJMoa032295 PMID: doi: 10.1056/NEJMoa032295 15028824 doi: 10.1056/NEJMoa032295
Hosch S B, Knoefel W T, Metz S, Stoecklein N, Niendorf A, Broelsch C E, Izbicki J R. Early lymphatic tumor cell dissemination in pancreaticcancer: frequency and prognostic significance. Pancreas, 1997, 15(2): 154–159 doi:10.1097/00006676-199708000-00007 PMID: doi: 10.1097/00006676-199708000-00007 9260200 doi: 10.1097/00006676-199708000-00007
Tawada K, Yamaguchi T, Kobayashi A, Ishihara T, Sudo K, Nakamura K, Hara T, Denda T, Matsuyama M, Yokosuka O. Changes in tumor vascularity depicted by contrast-enhanced ultrasonographyas a predictor of chemotherapeutic effect in patients with unresectablepancreatic cancer. Pancreas, 2009, 38(1): 30–35 doi:10.1097/MPA.0b013e318183ff73 PMID: doi: 10.1097/MPA.0b013e318183ff73 19117085 doi: 10.1097/MPA.0b013e318183ff73
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein W O, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy withgemcitabine vs observation in patients undergoing curative-intentresection of pancreatic cancer: a randomized controlled trial. JAMA, 2007, 297(3): 267–277 doi:10.1001/jama.297.3.267 PMID: doi: 10.1001/jama.297.3.267 17227978 doi: 10.1001/jama.297.3.267
Jin C, Yao L, Long J, Fu D L, Yu X J, Xu J, Yang F, Ni Q X. Effect of multiple-phase regional intra-arterialinfusion chemotherapy on patients with resectable pancreatic headadenocarcinoma. Chin Med J (Engl), 2009, 122(3): 284–290 PMID: 19236805
Sultana A, Smith C T, Cunningham D, Starling N, Neoptolemos J P, Ghaneh P. Meta-analyses of chemotherapyfor locally advanced and metastatic pancreatic cancer. J Clin Oncol, 2007, 25(18): 2607–2615 doi:10.1200/JCO.2006.09.2551 PMID: doi: 10.1200/JCO.2006.09.2551 17577041 doi: 10.1200/JCO.2006.09.2551
